

References

I-172

1. Cherukuri A, Cahan H, Tuyl AV, et al. Immunogenicity to cerliponase alfa, an enzyme replacement therapy for patients with CLN2 disease: Results from a phase 1/2 study. *Clin Immunol.* 2018;197:68-76.
2. Fietz M, Al Sayed M, Burke D, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. *Mol Genet Metab.* 2016;119(1-2):160-167.
3. Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. *N Engl J Med.* 2018;378:1898-1907.
4. De los Reyes E, Lehwald L, Ausutine E, et al. Intracerebroventricular cerliponase alfa for CLN2 disease: Clinical practice considerations from US clinic. *Pediatr Neurol.* 2020;110:64-70.
5. Kim A, Grover A, Hammon K, et al. Clinical pharmacokinetics and pharmacodynamics of cerliponase Alfa, enzyme replacement therapy for CLN2 disease by intracerebroventricular administration. *Clin Transl Sci.* 2021;14(2):635-644.
6. Wibbeler E, Wang R, Reyes EL, et al. Cerliponase alfa for the treatment of atypical phenotypes of CLN2 Disease: A retrospective case series. *J Child Neurol.* 2021;36(6):468-474.
7. Brineura (cerliponase alfa) injection, for intraventricular use [package insert]. BioMarin Pharmaceutical Inc. Novato, CA. Revised 03/2020.
8. Cerliponase Alfa In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 18, 2017.
9. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Cerliponase alfa.
10. Micromedex DrugDex Compendium®. 2022. Cerliponase alfa.